Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 7
Submit an article Journal homepage
595
Views
46
CrossRef citations to date
0
Altmetric
Reviews

Reovirus-based therapy for cancer

Kevin Kelly University of Texas Health Science Center, Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Road, San Antonio, Texas 78229, USA +1 210 450 1797; +1 210 692 7502; [email protected]
,
Steffan Nawrocki University of Texas Health Science Center, Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Road, San Antonio, Texas 78229, USA +1 210 450 1797; +1 210 692 7502; [email protected]
,
Alain Mita University of Texas Health Science Center, Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Road, San Antonio, Texas 78229, USA +1 210 450 1797; +1 210 692 7502; [email protected]
,
Matthew Coffey Oncolytics Biotech Inc, 210, 1167 Kensington Cres NW, Calgary, Alberta, Canada
,
Francis J Giles University of Texas Health Science Center, Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Road, San Antonio, Texas 78229, USA +1 210 450 1797; +1 210 692 7502; [email protected]
&
Monica Mita University of Texas Health Science Center, Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Road, San Antonio, Texas 78229, USA +1 210 450 1797; +1 210 692 7502; [email protected]
Pages 817-830 | Published online: 15 Jun 2009

Bibliography

  • Jackson GG, Muldoon RL. Viruses causing common respiratory infection in man. IV. Reoviruses and Adenoviruses. J Infect Dis 1973;128(6):811-66
  • Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963;77:29-37
  • Stoeckel J, Hay JG. Drug evaluation: reolysin–wild-type reovirus as a cancer therapeutic. Curr Opin Mol Ther 2006;8(3):249-60
  • Yap TA, Brunetto A, Pandha H, et al. Reovirus therapy in cancer: has the orphan virus found a home? Expert Opin Investig Drugs 2008;17(12):1925-35
  • Minuk GY, Paul RW, Lee PW. The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 1985;16(1):55-60
  • Norman KL, Lee PW. Reovirus as a novel oncolytic agent. J Clin Invest 2000;105(8):1035-8
  • Tai JH, Williams JV, Edwards KM, et al. Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J Infect Dis 2005;191(8):1221-4
  • Barton ES, Connolly JL, Forrest JC, et al. Utilization of sialic acid as a coreceptor enhances reovirus attachment by multistep adhesion strengthening. J Biol Chem 2001;276(3):2200-11
  • Barton ES, Forrest JC, Connolly JL, et al. Junction adhesion molecule is a receptor for reovirus. Cell 2001;104(3):441-51
  • Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3(7):489-501
  • Alain T, Kim TS, Lun X, et al. Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol Ther 2007;15(8):1512-21
  • Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6(10):764-75
  • Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977;54(4):307-15
  • Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978;28(2):444-9
  • Kim M, Chung YH, Johnston RN. Reovirus and tumor oncolysis. J Microbiol 2007;45(3):187-92
  • Strong JE, Tang D, Lee PW. Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology 1993;197(1):405-11
  • Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 1996;70(1):612-6
  • Norman KL, Lee PW. Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 2005;10(12):847-55
  • Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991;349(6305):117-27
  • Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49(17):4682-9
  • Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82
  • Hermanson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992;52(11):3213-9
  • Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
  • Campbell SL, Khosravi-Far R, Rossman KL, et al. Increasing complexity of Ras signaling. Oncogene 1998;17(11 Reviews):1395-413
  • Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. Embo J 1998;17(12):3351-62
  • Marcato P, Shmulevitz M, Lee PW. Connecting reovirus oncolysis and Ras signaling. Cell Cycle 2005;4(4):556-9
  • Panniers R, Henshaw EC. A GDP/GTP exchange factor essential for eukaryotic initiation factor 2 cycling in Ehrlich ascites tumor cells and its regulation by eukaryotic initiation factor 2 phosphorylation. J Biol Chem 1983;258(13):7928-34
  • Shmulevitz M, Marcato P, Lee PW. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 2005;24(52):7720-8
  • Norman KL, Hirasawa K, Yang AD, et al. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004;101(30):11099-104
  • Wang G, Barrett JW, Stanford M, et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci USA 2006;103(12):4640-5
  • Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274(5286):373-6
  • He B, Gross M, Roizman B. The γ134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the αsubunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997;94(3):843-8
  • Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001;3(8):745-50
  • Bergmann M, Romirer I, Sachet M, et al. A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res 2001;61(22):8188-93
  • Collette J, Ulku AS, Der CJ, et al. Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Int J Cancer 2004;112(2):190-9
  • Chambers AF, Colella R, Denhardt DT, Wilson SM. Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells. Mol Carcinog 1992;5(3):238-45
  • Marcato P, Shmulevitz M, Pan D, et al. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 2007;15(8):1522-30
  • Clarke P, Meintzer SM, Wang Y, et al. JNK regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells. J Virol 2004;78(23):13132-8
  • Connolly JL, Rodgers SE, Clarke P, et al. Reovirus-induced apoptosis requires activation of transcription factor NF-κB. J Virol 2000;74(7):2981-9
  • Pruitt K, Pruitt WM, Bilter GK, et al. Raf-independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for Ras transformation. J Biol Chem 2002;277(35):31808-17
  • Song L, Ohnuma T, Gelman IH, Holland JF. Reovirus infection of cancer cells is not due to activated Ras pathway. Cancer Gene Ther 2009;16(4):382. Published online 24 October 2008, doi:10.1038/cgt.2008.84
  • Wilcox ME, Yang W, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001;93(12):903-12
  • van den Wollenberg DJ, van den Hengel SK, Dautzenberg IJ, et al. A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting. Gene Ther 2008;15(24):1567-78
  • van Houdt WJ, Smakman N, van den Wollenberg DJ, et al. Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles. Cancer Gene Ther 2008;15(5):284-92
  • Ikeda Y, Nishimura G, Yanoma S, et al. Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris Nasus Larynx 2004;31(4):407-12
  • Errington F, White CL, Twigger KR, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 2008;15(18):1257-70
  • Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282(5392):1332-4
  • Hirasawa K, Nishikawa SG, Norman KL, et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002;62(6):1696-701
  • Etoh T, Himeno Y, Matsumoto T, et al. Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 2003;9(3):1218-23
  • Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002;13(5):641-52
  • Kilani RT, Tamimi Y, Hanel EG, et al. Selective reovirus killing of bladder cancer in a co-culture spheroid model. Virus Res 2003;93(1):1-12
  • Alain T, Hirasawa K, Pon KJ, et al. Reovirus therapy of lymphoid malignancies. Blood 2002;100(12):4146-53
  • Zhang WE, Kolb EA. Reolysin®, an unmodified Reovirus, has significant anti-tumor activity in childhood sarcomas. AACR Meeting Abstracts 2006;(1):1017-b-
  • Takayama T, Ohi M, Hayashi T, et al. Analysis of K-ras, APC, and β-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 2001;121(3):599-611
  • Smakman N, van der Bilt JD, van den Wollenberg DJ, et al. Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther 2006;13(8):815-8
  • Smakman N, van den Wollenberg DJ, Borel Rinkes IH, et al. Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. J Virol 2005;79(23):14981-5
  • Hata Y, Etoh T, Inomata M, et al. Efficacy of oncolytic reovirus against human breast cancer cells. Oncol Rep 2008;19(6):1395-8
  • Yang WQ, Senger DL, Lun XQ, et al. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther 2004;11(21):1579-89
  • Yang WQ, Senger D, Muzik H, et al. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res 2003;63(12):3162-72
  • Hanel EG, Xiao Z, Wong KK, et al. A novel intravesical therapy for superficial bladder cancer in an orthotopic model: oncolytic reovirus therapy. J Urol 2004;172(5 Pt 1):2018-22
  • Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707-12
  • Bryson JS, Cox DC. Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia. Cancer Immunol Immunother 1988;26(2):132-8
  • Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84(2):380-3
  • Thirukkumaran CM, Luider JM, Stewart DA, et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 2003;102(1):377-87
  • Hirasawa K, Nishikawa SG, Norman KL, et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003;63(2):348-53
  • White CL, Twigger KR, Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008;15(12):911-20
  • Qiao J, Wang H, Kottke T, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008;14(1):259-69
  • Ilett EJ, Prestwich RJ, Kottke T, et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther 2009. Published online 12 March 2009; doi:10.1038/gt.2009.29
  • Paiva LR, Binny C, Ferreira SC Jr, Martins ML. A multiscale mathematical model for oncolytic virotherapy. Cancer Res 2009;69(3):1205-11
  • Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005;433(7028):887-92
  • Benencia F, Courrèges MC, Conejo-García JR, et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005;12(5):789-802
  • Diaz RM, Galivo F, Kottke T, et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007;67(6):2840-8
  • Kedl RM, Rees WA, Hildeman DA, et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000;192(8):1105-13
  • Errington F, Steele L, Prestwich R, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008;180(9):6018-26
  • Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811
  • Prestwich RJ, Errington F, Ilett EJ, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008;14(22):7358-66
  • Prestwich RJ, Ilett EJ, Steele L, Errington F. The importance of the immune system in reovirus therapy. Clin Oncol (R Coll Radiol) 2008;20(10):769. Published online 27 September 2008, doi:10.1016/j.clon.2008.08.004
  • Nagano S, Perentes JY, Jain RK, Boucher Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res 2008;68(10):3795-802
  • Morris DG, Forsyth P, Paterson AHG, et al. A phase 1 clinical trial evaluating intralesional reolysin (reovirus) in histologically confirmed malignancies [abstract 92]. Proc Am Soc Clin Oncol 2002;21:24
  • Yang WQ, Lun X, Palmer CA, et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 2004;10(24):8561-76
  • Chiocca EA, Abbed KM, Tatter S, et al. A Phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004;10(5):958-66
  • Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7(10):867-74
  • Forsyth P, Roldán G, George D, et al. A Phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008;16(3):627-32
  • McKenna WG, Muschel RJ, Gupta AK, et al. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003;22(37):5866-75
  • Twigger K, Vidal L, White CL, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 2008;14(3):912-23
  • Vidal-Boixader L, Karavasilis V, Beirne D, et al. Phase I trial of intratumoral administration of reovirus type 3 with radiation in patients with advanced malignancies. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):14009
  • Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008;14(21):7127-37
  • Comins C, Spicer J, Protheroe, A, et al. A Phase I study to evaulate systemic wild-type reovirus (Reolysin®) in combination with Docetaxel in patients with advanced malignancies. in Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. 2009. Banff, Alberta. Available from: http://www.oncolyticsbiotech.com/iSBTc_docetaxel_REO_010_Nov.pdf [Last accessed 4 May 2009]
  • Gollamudi R, Desai K, Chaudhary I, et al. Pharmacodynamic and safety study of reolysin in patients with advanced solid tumors. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):14004
  • Harrington K. Clinical Trials with Oncolytic Virotherapy – moving beyond Phase I Trials into combinations with standard therapeutics, Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. 2009. Banff, Alberta
  • Verdin EM, Maratos-Flier E, Kahn CR, et al. Visualization of viral clearance in the living animal. Science 1987;236(4800):439-42
  • Soefje SA, Sarantopoulos J, Sankhala KK, et al. A phase II study of intravenous reolysin (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2008;26 No15S(20 Suppl):10568
  • Clinical trials. Oncolytics Biotech Inc. Calgary, Alberta, Canada. 2009. Available from: http://www.oncolyticsbiotech.com/clinical.html. [Last accessed 4 May 2009]
  • Rougier P, Stroiakovski D, Köhne C, et al. Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer (mCRC): updated survival data and influence of KRAS status on outcome in the CRYSTAL study [abstract 443]. Gastrointestinal Cancers Symposium 2009

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.